Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol vs Tiotropium in Moderate-to-Severe COPD
NCT00900731Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of indacaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Trough Forced Expiratory Volume in 1 Second at 12 weeks. Started Jun 2009; status: completed.
02
Drugs
indacaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00900731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00900731.